Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

N-[[1-(2-phenylethyl)pyrrolidin-2-yl]methyl]cyclohexanecarboxamides as selective 5-HT1A receptor agonists.

M Fujio1, Y Togo, H Tomozane

  • 1Exploratory Research 1, Drug Discovery Laboratories, Pharmaceutical Research Division, Yoshitomi Pharmaceutical Industries, Ltd., Iruma, Saitama, Japan. fujo@yoshitomi.co.jp

Bioorganic & Medicinal Chemistry Letters
|April 1, 2000
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a novel method for operating magnetic particles, Magtration Technology, and its use for automating nucleic acid purification.

Journal of bioscience and bioengineering·2005
Same author

Involvement of the bed nucleus of the stria terminalis activated by the central nucleus of the amygdala in the negative affective component of morphine withdrawal in rats.

Neuroscience·2005
Same author

Unexpectedly small ortho-oxygen substituent effects on stabilities of benzylic carbocations.

Journal of the American Chemical Society·2004
Same author

Dynamics for reaction of an ion pair in aqueous solution: reactivity of carboxylate anions in bimolecular carbocation-nucleophile addition and unimolecular ion pair collapse.

Organic letters·2001
Same author

Increased expression of queuosine synthesizing enzyme, tRNA-guanine transglycosylase, and queuosine levels in tRNA of leukemic cells.

Journal of biochemistry·2001
Same author

N-[1-(2-Phenylethyl)pyrrolidin-3-yl]-1-adamantanecarboxamides as novel 5-HT2 receptor antagonists.

Bioorganic & medicinal chemistry letters·2000

Researchers developed novel benzamides as selective agonists for the serotonin 5-HT1A receptor. Compound (7-(S)) demonstrated potent and selective 5-HT1A receptor agonistic activity, showing promise for therapeutic applications.

Area of Science:

  • Medicinal Chemistry
  • Neuropharmacology
  • Receptor Pharmacology

Background:

  • Serotonin 5-HT1A receptors are crucial targets for treating neurological and psychiatric disorders.
  • Developing selective agonists for 5-HT1A receptors remains a key objective in drug discovery.

Purpose of the Study:

  • To synthesize and characterize novel benzamide derivatives as potential selective agonists for the 5-HT1A receptor.
  • To evaluate the binding affinity and selectivity of synthesized compounds against 5-HT1A and other related receptors.

Main Methods:

  • Synthesis of a series of benzamide compounds.
  • In vitro radioligand binding assays to determine receptor affinity (Ki) and selectivity (IC50).
  • Evaluation of compound (7-(S)) for its activity at 5-HT1A, D2, and 5-HT2 receptors.

Related Experiment Videos

Main Results:

  • Compound (S)-N-[[1-(2-phenylethyl)pyrrolidin-2-yl]methyl]cyclohexanecarboxamide (7-(S)) was identified as a potent agonist.
  • Compound (7-(S)) exhibited high affinity for the 5-HT1A receptor (Ki = 0.49 nmol/L).
  • Demonstrated significant selectivity, with weak binding to D2 (IC50 >1000 nmol/L) and 5-HT2 receptors (Ki = 240 nmol/L).

Conclusions:

  • The synthesized benzamide derivative (7-(S)) is a potent and selective 5-HT1A receptor agonist.
  • This compound represents a promising lead for the development of novel therapeutics targeting 5-HT1A receptor-mediated pathways.
  • Further investigation into the therapeutic potential of (7-(S)) is warranted.